Compare KNSL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KNSL | ABVX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.5B |
| IPO Year | 2016 | N/A |
| Metric | KNSL | ABVX |
|---|---|---|
| Price | $373.18 | $109.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $455.40 | $128.42 |
| AVG Volume (30 Days) | 261.3K | ★ 714.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | ★ 21.65 | N/A |
| Revenue | ★ $1,873,987,000.00 | N/A |
| Revenue This Year | $6.46 | N/A |
| Revenue Next Year | $8.77 | $0.22 |
| P/E Ratio | $17.53 | ★ N/A |
| Revenue Growth | ★ 18.04 | N/A |
| 52 Week Low | $341.06 | $4.77 |
| 52 Week High | $512.76 | $148.83 |
| Indicator | KNSL | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 38.48 |
| Support Level | $365.55 | $107.99 |
| Resistance Level | $402.61 | $131.27 |
| Average True Range (ATR) | 10.96 | 5.11 |
| MACD | -0.19 | -1.73 |
| Stochastic Oscillator | 17.54 | 14.40 |
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.